BDTX-1535, a fourth generation EGFR inhibitor, targeting intrinsic and acquired resistance mutations in NSCLC

Tagrisso (osimertinib) - AstraZeneca

BDTX-1535 - Black Diamond Therap

Gilotrif (afatinib) - Boehringer Ingelheim

M. Lucas1; M. Merchant2; M. O'Connor3; S. Smith4; A. Trombino4; N. Waters4; S. Eathiraj2; E. Buck5

Sep 3, 2022